Core Viewpoint - The company, Xianju Pharmaceutical (002332.SZ), announced its participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, indicating a strategic move to secure market presence and enhance sales for its product, Vecuronium Bromide injection [1] Group 1 - The company will participate in the bidding process from October 27 to October 28, 2025 [1] - The product, Vecuronium Bromide injection, is intended for use as an adjunct in general anesthesia, specifically for tracheal intubation and muscle relaxation during surgery [1] - The company aims to have its product selected in this centralized procurement, which could lead to increased market access and sales opportunities [1]
仙琚制药(002332.SZ):注射用维库溴铵拟中选集采